Blue Trust Inc. Sells 693 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Blue Trust Inc. cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 40.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,026 shares of the medical equipment provider’s stock after selling 693 shares during the period. Blue Trust Inc.’s holdings in Zimmer Biomet were worth $108,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet during the fourth quarter worth $473,000. Geode Capital Management LLC raised its holdings in shares of Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp increased its stake in Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock valued at $2,884,000 after buying an additional 8,709 shares during the last quarter. Peddock Capital Advisors LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at $654,000. Finally, National Pension Service increased its stake in Zimmer Biomet by 3.8% in the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock valued at $39,893,000 after buying an additional 13,612 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 1.2 %

Shares of NYSE ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The firm has a market cap of $20.88 billion, a PE ratio of 23.57, a P/E/G ratio of 1.95 and a beta of 1.02. The company’s fifty day simple moving average is $105.86 and its 200 day simple moving average is $107.45. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the business earned $2.20 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is currently 21.57%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Wells Fargo & Company lifted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Raymond James lowered their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, Truist Financial reaffirmed a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.